|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
61,820,000 |
Market
Cap: |
190.41(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.83 - $4.13 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Poseida Therapeutics is a clinical-stage biopharmaceutical company. Co.'s chimeric antigen receptor T cell (CAR-T) product candidate includes P-BCMA-101, which is an autologous CAR-T being developed for the treatment of patients with metastatic castrate resistant prostate cancer. Co.'s dual CAR-T allogeneic program candidates include P-CD19CD20-ALLO1, which is an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications and some autoimmune disease. Co.'s gene therapy programs include P-OTC-101, which is an in vivo liver-directed gene therapy candidate for the treatment of ornithine transcarbamylase deficiency.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|